<DOC>
	<DOCNO>NCT02307825</DOCNO>
	<brief_summary>Justification : Chronic rhinosinusitis ( CRS ) one common inflammatory disease incidence prevalence superior 10 % . Unfortunately , 30 % patient respond standard medical surgical treatment , thus continuously increase symptomatologic socio-economic burden disease . Hypothesis : The investigator believe addition azithromycin ( AZI ) treatment regimen patient refractory CRS fail conventional medico-surgical treatment beneficial symptomatologic endoscopic level . Primary objective : 1- To evaluate whether Azithromycine 250 mg PO three time weekly effective control sign symptom CRS high-risk patient unresponsive standard management endoscopic sinus surgery ( ESS ) budesonide irrigation . Secondary objective : ) Validate simple concise treatment algorithm patient refractory standard CRS treatment ESS BUDI , addition low-dose AZI . ii ) Characterise define population deem `` high-risk '' standard CRS treatment failure evaluating : 1 ) demographic , 2 ) inflammatory state 3 ) nasal flora microbiome patient different follow-up point study . iii ) Explore mechanism AZI assess change inflammatory state nasal flora microbiome associate successful AZI therapy . Methods : Inclusion patient admit endoscopic sinus surgery ( ESS ) CRS operate surgeon ( MD ) . Following first postoperative visit ( 2 week ) , patient receive nasal irrigation budesonide ( BUDI ) twice daily 4 month re-evaluated . If failure treatment , patient eligible receive AZI randomize two group , AZI 250mg placebo three time week 4 month . At every follow-up , complete endoscopic exam perform , along sinus culture brush cytology . Population : All patient deem `` high-risk '' CRS admit ESS October 2014 October 2015 .</brief_summary>
	<brief_title>Azithromycin Patients With Chronic Rhinosinusitis Failing Medical Surgical Therapy</brief_title>
	<detailed_description />
	<mesh_term>Sinusitis</mesh_term>
	<criteria>Patients ≥1 follow criterion : history sinus surgery , first sinus surgery ≤38 year age , absolute eosinophilia ≥500 cells/mm , serum IgE level &gt; 150 kIU/L , Gram negative bacteria sinus culture , presence intraoperative eosinophilic mucin . Patients cystic fibrosis , invert papilloma , osteoma , mucoceles lesion base skull exclude . Patients elevate cardiovascular disease risk exclude randomized clinical trial part study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Azithromycin</keyword>
	<keyword>Endoscopic sinus surgery</keyword>
</DOC>